CCL5 and neoplasm: The upregulation of CCL5 expression in residual tumor tissue after treatment can be attributed to the increased release of CCL5 by CD8T cells stimulated by immunotherapy as well as the increased infiltration of CD8T cells into the TME caused by lenvatinib.36